Novel SGLT1/2 inhibitor safe, tolerable in NASH

BOSTON — Patients with non-alcoholic steatohepatitis treated with licogliflozin experienced dose-dependent improvement in alanine aminotransferase levels and other measures, according to study results presented at the Liver Meeting 2019.Licogliflozin (Novartis) is an inhibitor of sodium-glucose co-transporters 1 and 2 that limits the absorption of glucose from the gut and reabsorption from the kidney.“Dual inhibition of SGLT1 and SGLT2 with this medication in the gut and kidneys led us to significant weight loss in previous studies and favorable changes in metabolic parameters inRead More

Share on facebook
Share on twitter
Share on linkedin